JP2002504511A - 癌処置のためのエポチロンの使用 - Google Patents

癌処置のためのエポチロンの使用

Info

Publication number
JP2002504511A
JP2002504511A JP2000533117A JP2000533117A JP2002504511A JP 2002504511 A JP2002504511 A JP 2002504511A JP 2000533117 A JP2000533117 A JP 2000533117A JP 2000533117 A JP2000533117 A JP 2000533117A JP 2002504511 A JP2002504511 A JP 2002504511A
Authority
JP
Japan
Prior art keywords
epothilone
treatment
tumor
proliferative disease
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000533117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002504511A5 (cg-RX-API-DMAC7.html
Inventor
テレンス・オレイリー
マルクス・バルトマン
マニュエル・リッチマン
パメラ・コーエン
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9803905.0A external-priority patent/GB9803905D0/en
Priority claimed from GBGB9803907.6A external-priority patent/GB9803907D0/en
Priority claimed from GBGB9805937.1A external-priority patent/GB9805937D0/en
Priority claimed from GBGB9805936.3A external-priority patent/GB9805936D0/en
Priority claimed from US09/233,993 external-priority patent/US6302838B1/en
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2002504511A publication Critical patent/JP2002504511A/ja
Publication of JP2002504511A5 publication Critical patent/JP2002504511A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2000533117A 1998-02-25 1999-02-23 癌処置のためのエポチロンの使用 Withdrawn JP2002504511A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GBGB9803905.0A GB9803905D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9803907.6A GB9803907D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9805937.1A GB9805937D0 (en) 1998-03-19 1998-03-19 Organic compounds
GBGB9805936.3A GB9805936D0 (en) 1998-03-19 1998-03-19 Organic compounds
US09/233,993 1999-01-19
US09/233,993 US6302838B1 (en) 1998-02-25 1999-01-19 Cancer treatment with epothilones
US9805936.3 1999-01-19
US9805937.1 1999-01-19
US9803907.6 1999-01-19
US9803905.0 1999-01-19
PCT/EP1999/001147 WO1999043320A1 (en) 1998-02-25 1999-02-23 Use of epothilones for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011128592A Division JP2011173928A (ja) 1998-02-25 2011-06-08 癌処置のためのエポチロンの使用

Publications (2)

Publication Number Publication Date
JP2002504511A true JP2002504511A (ja) 2002-02-12
JP2002504511A5 JP2002504511A5 (cg-RX-API-DMAC7.html) 2010-08-19

Family

ID=27517450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000533117A Withdrawn JP2002504511A (ja) 1998-02-25 1999-02-23 癌処置のためのエポチロンの使用

Country Status (10)

Country Link
US (4) US6635666B2 (cg-RX-API-DMAC7.html)
EP (1) EP1056453B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002504511A (cg-RX-API-DMAC7.html)
AU (1) AU755944B2 (cg-RX-API-DMAC7.html)
BE (1) BE1011980A5 (cg-RX-API-DMAC7.html)
CA (1) CA2319752A1 (cg-RX-API-DMAC7.html)
FR (1) FR2775187B1 (cg-RX-API-DMAC7.html)
IT (1) ITMI990375A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ506187A (cg-RX-API-DMAC7.html)
WO (1) WO1999043320A1 (cg-RX-API-DMAC7.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525360A (ja) * 2002-03-01 2005-08-25 シエーリング アクチエンゲゼルシャフト 増殖過程に関連する脳疾患の処理へのエポチロンの使用
JP2005538044A (ja) * 2002-04-15 2005-12-15 プロテオジス アクチェンゲゼルシャフト 腫瘍の治療のための物質の使用
JP2006504727A (ja) * 2002-10-11 2006-02-09 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 多発性骨髄腫の処置のためのラクトン誘導体
JP2008514569A (ja) * 2004-09-24 2008-05-08 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 骨転移の治療へのエポチロンの使用
JP2009513486A (ja) * 2003-06-27 2009-04-02 ノバルティス アクチエンゲゼルシャフト エポチロンでの癌処置
JP2009536153A (ja) * 2006-04-05 2009-10-08 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
JP2019522989A (ja) * 2016-06-28 2019-08-22 アルマ マータ ステューディオラム — ユニバーシタ ディ ボローニャ TATκ−CDKL5融合タンパク質、組成物、製剤、及びそれらの使用

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59609305D1 (de) 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
ATE267197T1 (de) 1996-11-18 2004-06-15 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
CA2362047A1 (en) * 1999-02-26 2000-08-31 Larry Helson Treatment regimen for prostate cancer, initiated after androgen ablative therapy has started
WO2000050022A2 (en) * 1999-02-26 2000-08-31 Napro Biotherapeutics, Inc. Treatment regimen for hormone-sensitive cancers
US20050042275A1 (en) * 1999-08-04 2005-02-24 Jean-Claude Sonntag Epothilone compositions
US6414015B1 (en) 2000-01-28 2002-07-02 Utah State University Laulimalide microtubule stabilizing agents
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CA2434526C (en) * 2001-01-25 2011-11-01 Bristol Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
DE60225666T2 (de) * 2001-01-25 2009-04-16 Bristol-Myers Squibb Co. Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
SK8552003A3 (en) 2001-01-25 2004-06-08 Bristol Myers Squibb Co Parenteral formulation containing epothilone analogs
IL156988A0 (en) * 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
EE200300397A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaadid refraktaarsete kasvajate raviks
ATE554756T1 (de) 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
EP1372650B1 (en) * 2001-03-19 2008-11-19 Novartis AG Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
US6800653B2 (en) 2001-06-01 2004-10-05 Bristol-Myers Squibb Compnay Epothilone derivatives
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
JP5384777B2 (ja) * 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
AU2003235761A1 (en) 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
ATE350383T1 (de) * 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
HRP20050278A2 (en) 2002-09-23 2005-10-31 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
CA2510610A1 (en) * 2002-12-09 2004-06-24 Novartis Ag Microtubule stabilisers for treating stenosis in stents
US20040146632A1 (en) * 2003-01-23 2004-07-29 Cristina Sayman Effective multi-component penetrating and flavoring marinade
CN1870995A (zh) * 2003-09-02 2006-11-29 诺瓦提斯公司 使用埃坡霉素的癌症治疗
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
SI1817013T1 (sl) * 2004-11-18 2008-12-31 Bristol Myers Squibb Co Peleta z gastrorezistentno oblogo, ki vsebuje iksabepilon
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
DE102005008309A1 (de) * 2005-02-17 2006-08-24 Schering Ag Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone
JP2010510236A (ja) * 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク. 安定化させたmamlペプチドおよびその使用法
US20100173718A1 (en) 2007-06-20 2010-07-08 Saluc Technologies S.A. Convertible dining / billiard table
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2376100B1 (en) 2009-01-14 2017-10-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
US9862692B2 (en) * 2013-01-23 2018-01-09 The University Of Toledo Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US87634A (en) * 1869-03-09 Improvement in grain-storehouses
US220295A (en) * 1879-10-07 Improvement in hinges
US127432A (en) * 1872-06-04 Improvement in tuckers for sewing-machines
US142990A (en) * 1873-09-23 Improvement in machines for burnishing the shanks of boots and shoes
US203938A (en) * 1878-05-21 Improvement in wire fences
US260098A (en) * 1882-06-27 Rolls for longitudinally slitting railroad-rails
US34452A (en) * 1862-02-18 Improvement in railroad joints or chairs
US176429A (en) * 1876-04-25 Improvement in nut-locks
US253697A (en) * 1882-02-14 John halley and alexandee baee
US203876A (en) * 1878-05-21 Improvement in piston water-meters
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
AU6980094A (en) * 1993-07-15 1995-02-13 Pfizer Inc. Amide derivatives of 16-membered ring antibiotic macrolides
DE59609305D1 (de) * 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
ATE267197T1 (de) 1996-11-18 2004-06-15 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja) * 1997-04-18 2008-03-26 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ES2290993T3 (es) 1997-08-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
KR20080016756A (ko) 1998-02-05 2008-02-21 노파르티스 아게 유기화합물 함유 조성물
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
NZ508326A (en) 1998-06-18 2003-10-31 Novartis Ag A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B
US6121029A (en) * 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
AU4775299A (en) 1998-06-22 2000-01-10 Nicolaou, Kyriacos Costa Desmethyl epothilones
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
DE19848306A1 (de) * 1998-10-14 2000-04-20 Schering Ag Verfahren zur Herstellung von Epothilon B und Derivaten sowie Zwischenprodukte für dieses Verfahren
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
WO2001083800A2 (en) 2000-04-28 2001-11-08 Kosan Biosciences, Inc. Heterologous production of polyketides
KR101149124B1 (ko) * 2004-03-10 2012-05-25 가부시끼가이샤 구레하 아민계 염기성 화합물과 그의 용도

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN5001008509, J. Bio. Chem., 1997, Vol. 272, 2534−2541 *
JPN5001008510, Angew. Chem. Int. Ed. Engl., 1997, Vol. 36, 2093−2096 *
JPN5001008513, Cancer Res, 1995, Vol. 55, 2325−2333 *
JPN5001008516, Nature, 1997, Vol.387, 268−272 *
JPN5001008520, J. Biol. Chem., 1997, Vol.272, 17118−17125 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525360A (ja) * 2002-03-01 2005-08-25 シエーリング アクチエンゲゼルシャフト 増殖過程に関連する脳疾患の処理へのエポチロンの使用
JP2005538044A (ja) * 2002-04-15 2005-12-15 プロテオジス アクチェンゲゼルシャフト 腫瘍の治療のための物質の使用
JP2006504727A (ja) * 2002-10-11 2006-02-09 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 多発性骨髄腫の処置のためのラクトン誘導体
JP2009513486A (ja) * 2003-06-27 2009-04-02 ノバルティス アクチエンゲゼルシャフト エポチロンでの癌処置
JP2008514569A (ja) * 2004-09-24 2008-05-08 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 骨転移の治療へのエポチロンの使用
JP2009536153A (ja) * 2006-04-05 2009-10-08 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
JP2019522989A (ja) * 2016-06-28 2019-08-22 アルマ マータ ステューディオラム — ユニバーシタ ディ ボローニャ TATκ−CDKL5融合タンパク質、組成物、製剤、及びそれらの使用

Also Published As

Publication number Publication date
EP1056453B1 (en) 2010-10-06
AU2927999A (en) 1999-09-15
FR2775187A1 (fr) 1999-08-27
US7875601B2 (en) 2011-01-25
CA2319752A1 (en) 1999-09-02
NZ506187A (en) 2003-11-28
EP1056453A1 (en) 2000-12-06
US7091226B2 (en) 2006-08-15
BE1011980A5 (fr) 2000-03-07
WO1999043320A1 (en) 1999-09-02
US20040024033A1 (en) 2004-02-05
US6635666B2 (en) 2003-10-21
US20060223867A1 (en) 2006-10-05
AU755944B2 (en) 2003-01-02
FR2775187B1 (fr) 2003-02-21
US20050165071A1 (en) 2005-07-28
ITMI990375A1 (it) 1999-08-25
US20020028839A1 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
US7091226B2 (en) Cancer treatment with epothilones
US6302838B1 (en) Cancer treatment with epothilones
KR101943230B1 (ko) 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
JP2002504511A5 (cg-RX-API-DMAC7.html)
US20090069394A1 (en) Cancer treatment with epothilones
KR20040106422A (ko) 간암 및 다른 암 질병 치료용 에포틸론 유도체
US20030149088A1 (en) HIV treatment
US20020065234A1 (en) Method for treating neoplasia using combination chemotherapy
RU2242229C2 (ru) Применение эпотилонов для лечения рака
AU2003202508B2 (en) Use of epothilones for the treatment of cancer
EP3782620B1 (en) Pharmaceutical composition comprising 1,2-naphthoquinone derivative for use in preventing or treating acute myeloid or lymphoblastic leukemia
AU2004251444B2 (en) Cancer treatment with epothilones
KR20070037498A (ko) 에포틸론 조합물
US12447147B2 (en) Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions
ES2354193T3 (es) Utilización de epotilonas para el tratamiento del cáncer.
JP4571248B2 (ja) パートリシン誘導体の投与による腫瘍抑制法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100602

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100609

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100630

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110608

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110719